

1 **Changes in lung function and dyspnea perception in Colombian Covid-19 patients after a 12-**  
2 **week pulmonary rehabilitation program.**

3 12-week rehabilitation program in Covid-19

4 Carlos D Páez-Mora 1, Carolina Zona-Rubio1\*, Teddy Angarita-Sierra 2, Matilde E Rojas-Paredes  
5 1, Daniela Cano-Trejos 1.

6 1 cuidado Cardiorrespiratorio Research Group, Universidad Manuela Beltrán, Bogotá, Colombia.; 2  
7 Biodiversity for Society research group, Universidad Nacional de Colombia, La Paz headquarters,  
8 La Paz, Cesar, Colombia.

9 \*Corresponding author: Carolina Zona-Rubio, Research, Respiratory Therapy, Universidad  
10 Manuela Beltrán, Avenida circunvalar #60-00, 110231, Bogotá, Colombia. E-mail:  
11 [dczonar@unal.edu.co](mailto:dczonar@unal.edu.co)

12 BACKGROUND: Although moderate and severe COVID-19 patients have shown obstructive and  
13 restrictive disorders in pulmonary function after recovery from the disease, studies evaluating the  
14 effectiveness of rehabilitation programs that seek to improve lung function are scarce.

15 AIM: Herein, we evaluate changes in lung function and perceived dyspnea in Covid-19 patients after  
16 undergoing 12 weeks of a PR program.

17 DESIGN: Retrospective observational study

18 SETTING: Cesar, Colombia Neumocesar Pneumological Center.

19 POPULATION: 100 outpatients with a history of Covid-19

20 METHODS: We evaluated respiratory function using spirometry parameters, as well as the mMRC  
21 dyspnea scale for perceived dyspnea in 100 patients with a history of Covid-19. We used univariate  
22 and multivariate statistical approaches to assess changes in lung function and perceived dyspnea

23 before and after a PR program to determine whether gender, age, height, weight, comorbidities, and  
24 oxygen delivery system affect the recovery of lung function and perceived dyspnea.

25 RESULTS: We found that PR treatment has positive effects on respiratory pathologies caused by  
26 SARS-CoV-2 infection regardless of patient gender, indicating that rehabilitation provided benefits  
27 regardless of the physical characteristics of the patients. Both univariate and multivariate statistical  
28 analyses indicated that FVC, FEV1, FEF 25-75, and mMRC are robust diagnostic indicators of lung  
29 function recovery and perceived dyspnea. Both invasive and non-invasive positive pressure  
30 ventilatory support had deleterious effects on lung function prolongating patient recovery.

31 CONCLUSIONS: Rehabilitation programs can benefit patients facing respiratory pathologies caused  
32 by SARS-CoV-2 infection. Additional research on the long-term effects of the sequelae of Covid-19  
33 is needed. A large sample of patients is needed to clarify the effects of therapy on respiratory function.

34 CLINICAL REHABILITATION IMPACT: PR programs have positive effects on patients facing  
35 respiratory pathologies caused by SARS-CoV-2 infection.

36 Key words: pulmonary rehabilitation, SARS-CoV-2 infection, rehabilitation program.

37 **Introduction**

38 Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus. Many  
39 infected people develop mild to moderate respiratory illness and recover without requiring special  
40 treatment. However, approximately 20% of Covid-19 patients require medical attention (1). Peramo  
41 et al. (2) demonstrated that the persistence of some symptoms after recovery from the disease are  
42 sequelae associated with the infection. The destruction of the alveolar epithelium, lung consolidation,  
43 and extensive injury to alveolar epithelial cells are some of the pathophysiological manifestations  
44 observed (2). The deterioration of lung function has been observed after hospitalization due to the  
45 evolution of lung injury (3).

46 Disease progression leads to lung tissue damage, which stems from extensive injury to alveolar  
47 epithelial cells following infection. These alterations are more frequent in patients under mechanical  
48 ventilation. However, the presence of pulmonary alterations has been documented in pulmonary  
49 function tests of apparently healthy patients diagnosed with Covid-19 (2,4).

50 Spirometry is the best-known and low-cost respiratory function test, which involves evaluating the  
51 mechanical properties of the respiratory system through volumes and capacities; it provides relevant  
52 information for the classification of both obstructive and restrictive disorders (5). The most  
53 commonly used parameters in this test are forced vital capacity (FVC), forced expiratory volume in  
54 the first second (FEV1), and the FEV1/FVC ratio (6).

55 Studies evaluating the lung function of patients after Covid-19 infection are scarce. However, Torres  
56 Castro et al. (3) reported obstructive and restrictive disorders of the lung in both moderate and severe  
57 COVID-19 patients using spirometry. These authors also evaluated diffusion disorders using the  
58 diffusing capacity for carbon monoxide test (DLCO) and found that these were the most frequent  
59 alterations observed, even in patients with mild cases and patients without symptoms (7).

60 Approximately 40% of hospitalized Covid-19 patients have impaired lung function (8). This lesion  
61 has even been observed in patients with mild disease, which has motivated evaluations of lung  
62 function to characterize changes in the lung parenchyma and assess the need for treatment. Restrictive  
63 patterns are frequently observed between weeks 6 and 8 after discharge according to pulmonary  
64 function tests (9,10).

65 Pulmonary rehabilitation (PR) is a personalized multidisciplinary treatment that seeks to improve the  
66 physical and psychological conditions of patients with respiratory diseases. It has been used  
67 worldwide in patients with lung diseases such as chronic obstructive pulmonary disease (COPD) and  
68 can significantly improve lung function and quality of life. (10,11). It has also been used on patients  
69 in the recovery phase of Covid-19 (8-10).

70 Evaluations of lung function and dyspnea perception in patients undergoing rehabilitation programs  
71 are needed to improve our understanding of the sequelae of Covid-19 (12). Due to the scarcity of  
72 evidence-based guidelines regarding rehabilitation after COVID-19, there is an urgent need for  
73 studies to evaluate the lung function and dyspnea perception before and after PR programs (10,13,14).  
74 The Stanford Hall consensus for post-Covid-19 rehabilitation highlighted the need for more research  
75 on the sequelae of the disease and its long-term impact (10).

76 The aim of this study was to assess changes in lung function and perceived dyspnea in a group of  
77 patients diagnosed with Covid-19 after undergoing a 12-week PR program in a clinic in Colombia.  
78 The Ethical Guidelines for Human Research from the Declaration of Helsinki were followed, and  
79 ethics committee approval was obtained.

80

81 **Materials and methods**

82 *Study design*

83 Retrospective observational study was carried out and pre- and post-intervention lung function was  
84 evaluated. The data were accessed for research purposes on August 22, 2022, and a confidentiality  
85 agreement was signed with the institution to maintain the anonymity of the participants.

86 *Setting and Patients*

87 This study was conducted at NeumoCesar Pulmonary Center, Valledupar, Colombia. Approval was  
88 obtained from the ethics committee of Manuela Beltrán University in Bogotá, Colombia (TRCC-CE-  
89 I-2210009). The sample size was estimated using Slovin's formula as follows:

90 
$$n = \frac{N}{1 + Ne^2}$$

91 where  $n$  is the sample size,  $N$  is the total number of COVID-19 patients attended at NeumoCesar who  
92 received therapy (231 patients in this case),  $e$  is the maximum variability or margin of error (5% or  
93 0.05), and 1 is the probability of an event occurring. Resolving Slovin's formula, the sample size  
94 obtained was 100. Therefore, 100 patients diagnosed with COVID-19, who completed the PR  
95 program in 2022 and met the following inclusion and exclusion criteria, were included:

96 Inclusion criteria:

- 97 ● Post-covid-19 patients
- 98 ● Patients had been discharged from the hospital
- 99 ● Patients with 100% compliance with the PR program at the NeumoCesar institution.

100 Exclusion criteria:

101 • Serious arrhythmias, syncope induced by exercise or decompensated metabolic disorders without  
102 adequate management

103 • Coexistence of musculoskeletal or neurological problems that reduce mobility

104 • History of severe psychiatric disorder, cognitive disorders, or organic mental syndrome that  
105 prevents interaction or understanding instructions.

106 *Intervention*

107 Pre

108 Spirometry was performed, sociodemographic data were recorded, and FVC, FEV1, FEV1/FVC, FEF  
109 25–75, and PEF were evaluated; dyspnea was evaluated using the Modified Medical Research  
110 Council (mMRC) scale.

111 The PR program followed the recommendations of a previous publication of the Colombian Ministry  
112 of Health and Social Protection entitled "Interventions for a Pulmonary Rehabilitation Program" (16).

113 This is a conventional rehabilitation program, however, was tailored to each patient's individual needs  
114 and tolerance. During the sessions the modified BORG scale was used to assess the patient's effort.

115 Intensity was gradually adjusted by a therapist over the course of the rehabilitation in each session.

116 Intensity was defined according to hypoxemia, severity of the disease, age, among other variables.

117 Patients performed cardiorespiratory endurance training, accomplishing high-intensity intervals of 2  
118 to 3 minutes with 60 to 80% of the maximum cardiac capacity. We monitored the oxygen saturation  
119 of the patients with a pulse oximeter ensuring that the saturation range was always above 90%.

120 The rehabilitation program included different components such as pharmacological management,  
121 patient and family education, nutritional follow-up, psychosocial support, daily living aid training,  
122 vocational counseling, sexuality, and energy conservation techniques. These components were led by

123 a multidisciplinary team that included a Doctor, Respiratory Therapist, Physiotherapist, Nurse,  
124 Nutritionist, Occupational Therapist, among others at NeumoCesar institution.

125 The PR program at the Pneumological Center comprised three sessions a week for 3 months. Vital  
126 signs were monitored and recorded before, during, and after each session. The sessions were 45 min  
127 and included (1) 20 min of aerobic exercise on a recumbent bike along with a respiratory stimulator  
128 comprising 3 balloons, 1200 ml. The respiratory stimulator was used for 4 series of 5 repetitions and  
129 adjusted to accommodate the tolerance of each patient; (2) 20 minutes of varied physical exercise  
130 including resistance, flexibility, and strength; (3) and 5 minutes of cool down.

131 Post

132 Spirometry was performed after completing the rehabilitation program. The mMRC dyspnea  
133 questionnaire was also assessed.

#### 134 *Respiratory function and dyspnea assessments*

135 Respiratory function was assessed through spirometry tests performed using the MiniBox SN  
136 2021102368-PulmOne system with easy one connects; Minibox version: 3.1.1.19 software was used  
137 to record patient data such as age, gender, height, and weight at the beginning and end of the  
138 rehabilitation program. Dyspnea was assessed with the mMRC scale (Modified Medical Research  
139 Council) defined by the Medical Research Council (15), which was used as a self-assessment tool to  
140 measure the degree of disability of the patient due to dyspnea in daily activities on a scale from 0 to  
141 4 (Table 1).

#### 142 **Tables**

143 Table 1. Parameters and criteria employed to evaluate respiratory function and dyspnea.

---

### **Respiratory function**

---

---

Forced vital capacity (FVC), expressed in liters, its normal values were  $\geq 80\%$  of the predicted value.

---

Forced expiratory volume in one second (FEV1), expressed in liters, and its normal value was  $\geq 80\%$  of the predicted value.

---

Ratio between forced expiratory volume in one second and forced vital capacity (FEV1/FVC) normal value  $> 70\%$  of the predicted value.

---

Forced expiratory flow 25 - 75 (FEF25-75%), measured in liters, and its normal value  $> 65\%$  of the predicted value (5).

---

Peak expiratory flow (PEF), the maximal flow that can be exhaled, measured in liters.

---

### **mMRC dyspnea scale**

---

0 no dyspnea except during strenuous exercise

---

1 shortness of breath when running on a level surface or up a slight incline

---

2 walks slower than people of the same age on a level surface due to shortness of breath or has to stop to catch breath when walking at a normal pace on a level surface.

---

3 stops to catch breath after walking  $\sim 100$  m or after a few minutes on a level surface

---

4 too out of breath to leave the house, or out of breath while dressing or undressing

---

144

145 *Statistical analysis*



146 We evaluated differences in respiratory function by gender before and after therapy using a univariate  
147 approach. We compared the age ranges by gender of the patients who completed the PR program  
148 using a Welch's t-test (*t*). We compared the variability in forced volume capacity (FVC), forced  
149 expiratory volume (FEV 1), peak expiratory flow (PEF), forced expiratory flow from 25 to 75% (FEF  
150 25-75), and FEV1/FVC ratio using ANOVA (F= Fisher's F test; df= degrees of freedom; p =  
151 probability of significance). We analyzed the variability in mMRC using a non-parametric ANOVA,  
152 and a Kruskal-Wallis test (*H*) was used to measure the central tendency of the samples (17). We  
153 explored whether the age, height, or weight of the patients affected the variability observed in the  
154 respiratory function through ANCOVA. We also assessed whether comorbidities by gender and the  
155 oxygen delivery system used affect the FVC variability observed before and after therapy using nested  
156 ANOVA. For all univariate analyses, we evaluated assumptions of normality and homogeneity of  
157 variances using a Shapiro–Wilk test and Levene test, respectively.

158 We used a multivariable approach to assess the correlation and discrimination capacity of the  
159 respiratory responses before and after therapy. We conducted a multidimensional scaling test (MDS)  
160 to determine which of the respiratory responses showed greater variability; the respiratory response  
161 that explains the differences observed indicates the success/failure of the intervention. MDS allows  
162 similarities (or distances) in respiratory function to be represented as points in a high dimensional  
163 space, which are reduced into a lower dimensional space, thereby providing a visual indication of the  
164 similarity (or dissimilarity) (18,19). It also permits the identification of whether one cluster of patients  
165 is dimensionally distinct from another via the identification of the respiratory function with the  
166 highest variability and discrimination degree without linearity assumptions or a priori clustering (20).  
167 The goodness of fit between the fitted and observed distances was measured using “Kruskal’s stress”  
168 (S) (20,21), which is the average of the deviations between the end and the initial spatial distances  
169 normalized to take values between 0 and 1. Values near 1 indicate the worst fit, and values near 0  
170 indicate the best fit. However, values between 0.025 and 0.05 are considered good values, < 0.025

171 are excellent, and values equal to 0 are perfect (19). A linear discriminant analysis was conducted to  
172 identify respiratory responses with the greatest discrimination capacity between pre- and post-therapy  
173 performance.

174 All statistical analyses were performed using the software Rwizard 4.3 (19) and the following R  
175 packages: car (21), hier.part (22), lawstat (23) nortest (24), overlap (25), stat (26), and usdm (27).

#### 176 *Data availability*

177 The data associated with the paper are not publicly available; however, they are available from the  
178 corresponding author on reasonable request.

179

#### 180 *Ethical considerations*

181 Before being included in the study, patients who met the inclusion criteria had to give their written  
182 consent to participate in the study. Written informed consent was obtained from adult participants  
183 ( $\geq 18$  years). The risks and benefits associated with participation in the study were clearly explained  
184 to each patient. The study was conducted in accordance with the Declaration of Helsinki ethical  
185 guidelines for research in humans. Likewise, approval was obtained from the ethics committee of  
186 Manuela Beltrán University (TRCC-CE-I-2210009).

#### 187 **Results**

188 A total of 100 adult patients were included in the study (Men =42; women = 58; ratio = 1:1.4). The  
189 age range was broad for both genders, and no significant difference in the age range was observed  
190 between them ( $t = 0.058$ ,  $df = 80.36$ ,  $P = 0.95$ ; Table 2). Respiratory function differed greatly before  
191 and after therapy; however, differences in pre- and post-therapy performance were low within each  
192 gender (Table 2). Men and women exhibited significant differences in FVC ( $F = 19.47$ ,  $df = 3$ ,  $P$   
193  $< 0.0001$ ), FEV1 ( $F = 22.49$ ,  $df = 3$ ,  $P = < 0.0001$ ), and mMRC ( $H = 99.022$ ,  $df = 3$ ,  $P < 0.0001$ ) before

194 and after therapy (Fig. 1). However, no differences were observed in PEF and FEF 25-75%, as well  
195 as in the FEV1/FVC ratio (Fig. 2). ANCOVA showed that age, height, or weight was not correlated  
196 with FVC, FEV1, or MRC (Table 3), indicating that these variables had no effect on the significant  
197 differences observed before and after therapy.

198 Nested ANOVA indicated that the absence or presence of comorbidities in men and women  
199 showing significant differences in FVC was associated with the oxygen delivery system that  
200 had been used to treat SARS-CoV-2 infection ( $F= 22.49$ ,  $df= 3$ ,  $P=<0.0001$ ); the VMN and  
201 VMNI systems were correlated with FVC values under 70%, and the low-flow system and  
202 non-oxygen delivery were correlated with FVC values over 70%. However, comorbidities  
203 did not affect differences observed between men and women in FVC and FEV1.

204 MDS revealed significant dissimilarities ( $S= 0.029$ ) in the respiratory function of patients before and  
205 after therapy (Figure 3A), indicating that therapy had positive effects on the respiratory pathologies  
206 caused by SARS-CoV-2 infection. In addition, the MDS suggested that FEF 25-75% and mMRC are  
207 robust diagnostic indicators of the patient recovery process because these respiratory function  
208 variables were the most variable and had the highest discrimination degree. The linear discriminant  
209 analysis confirmed that the therapy had positive effects on patients recovering from respiratory  
210 pathologies caused by SARS-CoV-2 infection, as indicated by the pronounced differences observed  
211 before and after therapy for each gender (Figure 3B-D). The first canonical axis explained 91.3% of  
212 the variance and was correlated with differences in FVC and FEV1; the second canonical axis  
213 explained 7.76% of the variance and was correlated with differences in MRC and FEF 25-75 (Figure  
214 3C). The linear discriminant analysis also yielded the same diagnostic indicators for the patient  
215 recovery process as were identified in the ANOVA and MDS. However, the cross-validation  
216 percentage was moderate (55.5%), indicating that large patient sampling is required for the  
217 discrimination function to achieve a higher classification accuracy of the respiratory function before  
218 and after therapy.

219 Table 2. Descriptive data of the patients who completed the PR program and variables assessed.

<b>Patients 'trait</b>	<b>Women (N = 42)</b>	<b>Men (N = 58)</b>
<b>Body measurements</b>		
Height (m)	1.44–1.76 ( $\bar{X}$ =1.61)	1.52–1.90 ( $\bar{X}$ =1.73)
Weight (kg)	48–110 ( $\bar{X}$ =74)	42–128 ( $\bar{X}$ =80)
Age	22–86 ( $\bar{X}$ =53.6)	19–81 ( $\bar{X}$ =52.8)
<b>Oxygen delivery system</b>		
Invasive ventilation (IV)	6	10
Non-invasive ventilation (NIV)	17	28
Low flow	9	8
None	10	12
<b>Comorbidities</b>		
Asthma	6	3
COPD	5	2
Diabetes	1	2
High blood pressure	4	5
Hypothyroidism	2	0
Obesity	2	1
OSA	0	1
Non-comorbidities	22	45
<b>Marital status</b>		
None	26	40
Partner	16	19
<b>Health insurance</b>		
Contributory	38	51
Contributory + Prepaid insurance	1	2

---

Subsidized	3	6
------------	---	---

---

220


221 Table 3. ANCOVA for assessing the effects of age, height, and weight of the patients on  
 222 respiratory function variables that showed significant differences before and after therapy.

---

<b>Respiratory output</b>	<b>Age</b>	<b>Height</b>	<b>Weight</b>
<b>FVC</b>	F= 0.77, P= 0.37	F= 0.95, P= 0.32	F=0.035, P= 0.85
<b>FEV1</b>	F= 0.007, P= 0.98	F= 0.27, P= 0.60	F= 0.031, P= 0.86

---

223



225

226 Figure 1. Differences by gender in the respiratory function before and after therapy using a  
 227 univariate approach. (A-D) ANOVA for assessing respiratory responses before and after  
 228 therapy. FVC=forced volume capacity; FEV 1=forced expiratory volume; PEF= peak  
 229 expiratory flow; FEF 25-75= forced expiratory flow in 25 to 75% and FEV1/FVC1 ratio.

230


231

232

233


234

235 Figure 2



236

237 Figure 2. Differences by gender in peak expiratory flow function and dyspnea perception  
238 before and after therapy. (A) ANOVA for assessing the response of peak expiratory flow  
239 (PEF). (B) Non-parametric ANOVA using a Kruskal-Wallis test for assessing the perception  
240 of dyspnea. mMRC = Medical Research Council Dyspnea Scale.



242

243

244 Figure 3. (A) Multidimensional scaling test (MDS) assessing the respiratory function of  
 245 patients before and after therapy. The goodness of fit is indicated by the “Kruskal’s stress  
 246 (S).” Values near 1 indicate the worst fit, and values near 0 indicate the best fit. Values  
 247 between 0.025 and 0.05 are considered good values, values < 0.025 are excellent, and values  
 248 equal to 0 are perfect. (B-D) Linear discriminant analysis assessing the respiratory responses  
 249 of patients before and after therapy. (B) Biplot depicting the observed variability in



250 respiratory function of patients before and after therapy. (C) Canonical scores and structure  
251 of the linear discriminant analysis. (D) The length of the vector denotes the discrimination  
252 capacity of each respiratory function.

253

254

255 **Discussion**

256 The results of this study provide evidence that PR program has positive effects on both men and  
257 women patients recovering from respiratory pathologies caused by SARS-CoV-2 infection.  
258 Significant differences in lung function parameters such as FVC, FEV1, and mMRC were observed  
259 before and after therapy. Age, height, nor weight was correlated with significant differences in FVC,  
260 FEV1, and mMRC, indicating that the therapy provided benefits to all patients regardless of their  
261 physical characteristics.

262 FEV1 can be used to evaluate the degree of airway obstruction when used in conjunction with  
263 FEV1/FVC, which confirms the presence of obstruction. No significant differences were observed in  
264 FEV1/FVC before and after therapy, which confirms the presence of a restrictive pulmonary pattern  
265 and the absence of an obstructive pulmonary pattern, and changes in FEV1 before and after therapy  
266 were significant. Restrictive patterns are characteristic of pulmonary disorders that result in damage  
267 to the lung epithelium (16). The significant change in FVC reflects an improvement in pulmonary  
268 function following therapy, and this change was associated with the restrictive pattern caused by  
269 SARS-CoV-2 infection.

270 mMRC measures the perception of dyspnea, and it significantly improved after the therapy. This  
271 probably stemmed from the strengthening of the respiratory muscles. Rehabilitation also improves  
272 lung volume, oxygenation, and thus the perception of dyspnea. Resistance training during the early  
273 phases of rehabilitation likely improved the mechanical efficiency of the lungs; the observed  
274 improvement in lung function variables was similar to changes observed in patients undergoing  
275 rehabilitation programs following a diagnosis of COPD (28).

276 Our results are consistent with previous studies showing significant improvements in FVC, FEV1,  
277 and mMRC in Covid-19 patients after PR (29–32). Our findings are also consistent with the results  
278 of Liu et al. (12). In this study, a randomized controlled trial was conducted with 72 participants in

279 Huanggang, China, and changes in lung function were evaluated. Significant differences in some of  
280 the variables measured in our study, such as FVC, FEV1, and FEV1/FVC, before and after  
281 rehabilitation were detected. They also detected significant changes in DLCO and the 6-minute walk  
282 test before and after rehabilitation; however, these variables were not measured in our study.

283 The use of both invasive and non-invasive positive pressure ventilatory support during hospitalization  
284 was significantly associated with FVC lower than 70% compared with the group that did not use this  
285 support, which had FVC values higher than 70%. This might stem from the severity of Covid-19,  
286 which is directly related to the need to use this type of support (33). These results indicate that positive  
287 pressure ventilatory support might be associated with the deleterious effects on lung tissue. These are  
288 secondary to the difficulty of titrating the ventilatory parameters due to the pulmonary heterogeneity  
289 caused by the disease (34). In both cases, the lung tissue damage might be related to self-induced lung  
290 injury (P-SILI) or ventilator-induced lung injury (VILI) (34). Thus, both invasive and non-invasive  
291 positive pressure ventilatory support had deleterious effects on lung function, which prolonged patient  
292 recovery. Therefore, the damage caused by the ventilation systems, as well as the severe Covid-19  
293 symptoms that led to their use, explains why patients who required this type of support improved less  
294 than patients who did not require it.

295 The FEF 25-75% and mMRC parameters were robust diagnostic indicators of the patient recovery  
296 process, given that these respiratory responses were the most variable and had the highest  
297 discrimination capacity. This might be associated with changes in the small airway that are equivalent  
298 to approximately 80% of the extension of the lung parenchyma (35). Given that FEF 25-75% is the  
299 only spirometric measurement that assesses the small-caliber airway, additional studies that include  
300 more specific diagnostic methods for assessing changes in lung function in the small-caliber airway  
301 are needed (36–38). The long-term impacts of the sequelae of Covid-19 also merit further  
302 investigation; the use of a large sample of patients is needed to improve the ability to detect changes  
303 in respiratory function before and after therapy.

304 We found that PR had positive effects on recovery from respiratory pathologies caused by SARS-  
305 CoV infection and that it accelerated the recovery process. However, which techniques are optimal  
306 and how long the rehabilitation program should last remain unclear given that benefits have been  
307 observed in 2-week programs (29,39). Other studies have reported benefits in 6-week programs (28);  
308 in our study, positive effects were observed in a 12-week program (40).

309 PR accelerated the recovery of lung function and the perception of dyspnea in patients diagnosed with  
310 Covid-19. However, additional studies are needed to clarify whether rehabilitation method and  
311 program duration affect the benefits observed; the effectiveness of remote rehabilitation procedures  
312 such as Telemedicine also merits further study. Given the difficulty of access to medical facilities in  
313 Colombia, special effort is needed to ensure equal access to comprehensive care.

314

## 315 **Conclusions**

- 316 • A 12-week PR program resulted in significant changes in lung function in Colombian  
317 patients.
- 318 • The most pronounced changes were observed in the perception of dyspnea, FVC, and FEV1.  
319 Age, height, weight, and the presence of comorbidities were not correlated with significant  
320 changes observed between groups.
- 321 • Patients with a history of using positive pressure devices such as NIMV and IMV had FVC  
322 values less than 70%, a pattern that is associated with restrictive diseases.
- 323 • FEF 25-75 and MRC are robust diagnostic indicators of the patient recovery process given  
324 that these respiratory responses were the most variable and had the highest discrimination  
325 capacity. This is probably associated with the measurement of the small airway.

326

327

328 **Conflicts of interest**

329 The researchers that participated in this research do not report any conflict of interest. The authors  
330 certify that there is no conflict of interest with any financial organization regarding the material  
331 discussed in the manuscript.

332 **Funding**

333 The authors report no involvement in the research by the sponsor that could have influenced the  
334 outcome of this work.

335 **Authors' contributions**

336 Carlos Duvan Páez-Mora and author Carolina Zona-Rubio conceived and designed the study and  
337 wrote the manuscript; Teddy Angarita-Sierra analyzed and interpreted the data and wrote the  
338 manuscript; and Matilde E Rojas-Paredes and Daniela Cano-Trejos conceived the study and collected  
339 data. All authors contributed to drafts of the manuscript, and Carolina Zona-Rubio and Teddy  
340 Angarita-Sierra revised the manuscript. All authors read and approved the final version of the  
341 manuscript.

342 All authors contributed equally to the manuscript and read and approved the final version of the  
343 manuscript.

344 **Acknowledgments**

345 We thank the Neumocesar Pneumological Center and Doctor Edinson Valencia for their constant  
346 support and commitment to this research. We thank Christopher K Akcali for revising a draft of the  
347 manuscript.

348

349 **References**

- 350 1. CEPAL SE. La pandemia de enfermedad por Coronavirus Covid-19. CEPAL-UNDRR  
351 [Internet]. Vol. 1, Center for Disease Control and Prevention. 2021 [cited 2022 Oct 3].  
352 Available from: [https://www.paho.org/en/topics/coronavirus-infections/coronavirus-](https://www.paho.org/en/topics/coronavirus-infections/coronavirus-disease-covid-19-pandemic)  
353 [disease-covid-19-pandemic](https://www.paho.org/en/topics/coronavirus-infections/coronavirus-disease-covid-19-pandemic)
- 354 2. Peramo-Álvarez FP, López-Zúñiga MÁ, López-Ruz MÁ. Medical sequels of COVID-19  
355 [Internet]. Vol. 157, Medicina Clinica. Elsevier; 2021 [cited 2022 Oct 3]. p. 388–94.  
356 Available from: [/pmc/articles/PMC8157124/](https://pubmed.ncbi.nlm.nih.gov/35733179/)
- 357 3. Torres-Castro R, Vasconcello-Castillo L, Alsina-Restoy X, Solis-Navarro L, Burgos F,  
358 Puppo H, et al. Respiratory function in patients post-infection by COVID-19: a systematic  
359 review and meta-analysis [Internet]. Vol. 27, Pulmonology. Elsevier; 2021 [cited 2022 Oct  
360 3]. p. 328–37. Available from: [/pmc/articles/PMC7687368/](https://pubmed.ncbi.nlm.nih.gov/35733179/)
- 361 4. Naretto O, Emilio Á, Patricia PM, Angélica SM. Fisiopatología Pulmonar de la COVID-19.  
362 Rev Am Med Respir [Internet]. 2020 [cited 2022 Oct 3];4:402–9. Available from:  
363 [http://www.ramr.org/articulos/volumen\\_20\\_numero\\_4/articulos\\_revision/articulos\\_revision](http://www.ramr.org/articulos/volumen_20_numero_4/articulos_revision/articulos_revision_fisiopatologia_pulmonar_de_la_covid-19.pdf)  
364 [\\_fisiopatologia\\_pulmonar\\_de\\_la\\_covid-19.pdf](http://www.ramr.org/articulos/volumen_20_numero_4/articulos_revision/articulos_revision_fisiopatologia_pulmonar_de_la_covid-19.pdf)
- 365 5. Benítez-Pérez RE, Torre-Bouscoulet L, Villca-Alá N, Del-Río-Hidalgo RF, Pérez-Padilla R,  
366 Vázquez-García JC, et al. Espirometría: recomendaciones y procedimiento. NCT Neumol y  
367 Cirugía Tórax [Internet]. 2019 [cited 2022 Oct 22];78(S2):97–112. Available from:  
368 [www.medigraphic.org.mx](http://www.medigraphic.org.mx)
- 369 6. Kattainen S, Lindahl A, Vasankari T, Ollila H, Volmonen K, Piirilä P, et al. Lung function  
370 and exercise capacity 6 months after hospital discharge for critical COVID-19. BMC Pulm  
371 Med [Internet]. 2022 Dec 1 [cited 2022 Sep 14];22(1). Available from:  
372 <https://pubmed.ncbi.nlm.nih.gov/35733179/>
- 373 7. Ríos CPS. Función pulmonar y frecuencia de síndrome post-COVID-19 en pacientes

- 374 recuperados de neumonía por SARS-CoV-2 mediante enfoque completo de telemedicina.  
375 Respirar [Internet]. 2021 [cited 2022 Oct 3];13:128–37. Available from:  
376 [https://alatorax.org/es/publicaciones/respirar/34/funcion-pulmonar-y-frecuencia-de-](https://alatorax.org/es/publicaciones/respirar/34/funcion-pulmonar-y-frecuencia-de-sindrome-post-covid-19-en-pacientes-recuperados-de-neumonia-por-sars-cov-2-mediante-enfoque-completo-de-telemedicina)  
377 [sindrome-post-covid-19-en-pacientes-recuperados-de-neumonia-por-sars-cov-2-mediante-](https://alatorax.org/es/publicaciones/respirar/34/funcion-pulmonar-y-frecuencia-de-sindrome-post-covid-19-en-pacientes-recuperados-de-neumonia-por-sars-cov-2-mediante-enfoque-completo-de-telemedicina)  
378 [enfoque-completo-de-telemedicina](https://alatorax.org/es/publicaciones/respirar/34/funcion-pulmonar-y-frecuencia-de-sindrome-post-covid-19-en-pacientes-recuperados-de-neumonia-por-sars-cov-2-mediante-enfoque-completo-de-telemedicina)
- 379 8. Chen H, Shi H, Liu X, Sun T, Wu J, Liu Z. Effect of Pulmonary Rehabilitation for Patients  
380 With Post-COVID-19: A Systematic Review and Meta-Analysis. *Front Med* [Internet]. 2022  
381 Feb 21 [cited 2022 Sep 14];9. Available from: <https://pubmed.ncbi.nlm.nih.gov/35265644/>
- 382 9. Okan S, Okan F, Duran Yücesoy F. Evaluation of pulmonary function and exercise capacity  
383 after COVID-19 pneumonia. *Hear Lung* [Internet]. 2022 Jul 1 [cited 2022 Sep 14];54:1–6.  
384 Available from: <https://pubmed.ncbi.nlm.nih.gov/35305515/>
- 385 10. Barker-Davies RM, O’Sullivan O, Senaratne KPP, Baker P, Cranley M, Dharm-Datta S, et  
386 al. The Stanford Hall consensus statement for post-COVID-19 rehabilitation. *Br J Sports Med*  
387 [Internet]. 2020 Aug 1 [cited 2022 Sep 14];54(16):949–59. Available from:  
388 <https://pubmed.ncbi.nlm.nih.gov/32475821/>
- 389 11. Prunera-Pardell MJ, Padín-López S, Domenech-del Rio A, Godoy-Ramírez A. Efectividad  
390 de un programa de rehabilitación respiratoria en pacientes con enfermedad pulmonar  
391 obstructiva crónica. *Enferm Clin*. 2018 Jan 1;28(1):5–12.
- 392 12. Liu K, Zhang W, Yang Y, Zhang J, Li Y, Chen Y. Respiratory rehabilitation in elderly  
393 patients with COVID-19: A randomized controlled study. *Complement Ther Clin Pract*. 2020  
394 May 1;39:101166.
- 395 13. Paneroni M, Vogiatzis I, Bertacchini L, Simonelli C, Vitacca M. Predictors of Low Physical  
396 Function in Patients With COVID-19 With Acute Respiratory Failure Admitted to a Subacute  
397 Unit. *Arch Phys Med Rehabil*. 2021 Jun 1;102(6):1228–31.
- 398 14. Schaeffer MR, Cowan J, Milne KM, Puyat JH, Voduc N, Corrales-Medina V, et al.  
399 Cardiorespiratory physiology, exertional symptoms, and psychological burden in post-

- 400 COVID-19 fatigue. *Respir Physiol Neurobiol* [Internet]. 2022 Aug 1 [cited 2022 Sep 14];302.  
401 Available from: <https://pubmed.ncbi.nlm.nih.gov/35364291/>
- 402 15. Medical Research Council. MRC breathlessness scales: 1952 and 1959 – UKRI [Internet].  
403 1959 [cited 2023 Mar 2]. Available from: [https://www.ukri.org/publications/mrc-](https://www.ukri.org/publications/mrc-breathlessness-scales-1952-and-1959/)  
404 [breathlessness-scales-1952-and-1959/](https://www.ukri.org/publications/mrc-breathlessness-scales-1952-and-1959/)
- 405 16. Fernando L, Serna C, Bernal GB, General S. USO E INTERPRETACION DE LA  
406 ESPIROMETRIA [Internet].  
407 [https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/ENT/anexo-](https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/ENT/anexo-educativo-uso-espirometria.pdf)  
408 [educativo-uso-espirometria.pdf](https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/ENT/anexo-educativo-uso-espirometria.pdf). 2015 [cited 2023 Mar 7]. Available from:  
409 [https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/ENT/anexo-](https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/ENT/anexo-educativo-uso-espirometria.pdf)  
410 [educativo-uso-espirometria.pdf](https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/ENT/anexo-educativo-uso-espirometria.pdf)
- 411 17. Sokal R, Rohlf R. *Biometría: los principios y la práctica de la estadística en la investigación*  
412 *biológica*. 1st ed. Francisco S, editor. W. H FREEMAN; 1981.
- 413 18. Ren S, Frymier PD. Use of multidimensional scaling in the selection of wastewater toxicity  
414 test battery components. *Water Res* [Internet]. 2003 [cited 2022 Oct 22];37(7):1655–61.  
415 Available from: <https://pubmed.ncbi.nlm.nih.gov/12600394/>
- 416 19. Guisande C, Heine J, García-Roselló E, González-Dacosta J, Perez-Schofield BJJ,  
417 González-Vilas L, et al. FactorsR: An R Wizard application for identifying the mostm likely  
418 causal factors in controlling species Richness. *Diversity*. 2015;7(4):385–96.
- 419 20. Kruskal J, Wish M. *Multidimensional Scaling* [Internet]. 2455 Teller Road, Thousand Oaks  
420 California 91320 United States of America: SAGE Publications, Inc.; 1978. 98 p. Available  
421 from: <https://methods.sagepub.com/book/multidimensional-scaling>
- 422 21. Fox J, Weisberg S. *An R companion to applied regression*. SAGE, editor. 2019. 680 p.
- 423 22. Mac Nally R, Walsh CJ. Hierarchical partitioning public-domain software. *Biodivers*  
424 *Conserv* [Internet]. 2004 Mar [cited 2022 Oct 22];13(3):659–60. Available from:  
425 <https://link.springer.com/article/10.1023/B:BIOC.0000009515.11717.0b>



- 426 23. Hui W, Gel YR, Gastwirth JL. Lawstat: An R package for law, public policy and biostatistics.  
427 J Stat Softw [Internet]. 2008 [cited 2022 Oct 22];28(3). Available from:  
428 [https://www.academia.edu/33106134/lawstat\\_An\\_R\\_Package\\_for\\_Law\\_Public\\_Policy\\_and](https://www.academia.edu/33106134/lawstat_An_R_Package_for_Law_Public_Policy_and)  
429 [\\_Biostatistics](https://www.academia.edu/33106134/lawstat_An_R_Package_for_Law_Public_Policy_and)
- 430 24. Gross J, Ligges U. nortest: Tests for normality. <https://CRANR-project.org/package=nortest>,  
431 R Packag version 10-4. 2015;
- 432 25. Ridout MS, Linkie M. Estimating overlap of daily activity patterns from camera trap data. J  
433 Agric Biol Environ Stat [Internet]. 2009 [cited 2023 Mar 17];14(3):322–37. Available from:  
434 <https://link.springer.com/article/10.1198/jabes.2009.08038>
- 435 26. Maintainer B, Bolar K. Title Interactive Document for Working with Basic Statistical  
436 Analysis. 2022 [cited 2023 Mar 17]; Available from:  
437 <https://jarvisatharva.shinyapps.io/StatisticsPrimer/>
- 438 27. Naimi B, Hamm NAS, Groen TA, Skidmore AK, Toxopeus AG. Where is positional  
439 uncertainty a problem for species distribution modelling? *Ecography (Cop)*. 2014  
440 Feb;37(2):191–203.
- 441 28. Liu S ting, Zhan C, Ma Y jing, Guo C yang, Chen W, Fang X ming, et al. Effect of qigong  
442 exercise and acupressure rehabilitation program on pulmonary function and respiratory  
443 symptoms in patients hospitalized with severe COVID-19: a randomized controlled trial.  
444 *Integr Med Res* [Internet]. 2021 Jan 1 [cited 2022 Sep 14];10(Suppl). Available from:  
445 <https://pubmed.ncbi.nlm.nih.gov/34733607/>
- 446 29. Benavides-Cordoba V, Barros-Poblete M, Vieira RP, Mazzucco G, Fregonezi G, Torres-  
447 Castro R. Provision of pulmonary rehabilitation in Latin America 18 months after the  
448 COVID-19 pandemic: A survey of the Latin American Thoracic Association. *Chron Respir*  
449 *Dis* [Internet]. 2022 May 1 [cited 2022 Sep 14];19. Available from:  
450 <https://pubmed.ncbi.nlm.nih.gov/35616253/>
- 451 30. Zhu P, Wang Z, Guo X, Feng Z, Chen C, Zheng A, et al. Pulmonary Rehabilitation

- 452 Accelerates the Recovery of Pulmonary Function in Patients With COVID-19. *Front*  
453 *Cardiovasc Med* [Internet]. 2021 Jul 20 [cited 2022 Sep 14];8. Available from:  
454 <https://pubmed.ncbi.nlm.nih.gov/34355029/>
- 455 31. Puchner B, Sahanic S, Kirchmair R, Pizzini A, Sonnweber B, Wöll E, et al. Beneficial effects  
456 of multi-disciplinary rehabilitation in postacute COVID-19: an observational cohort study.  
457 *Eur J Phys Rehabil Med* [Internet]. 2021 Apr 1 [cited 2022 Sep 14];57(2):189–98. Available  
458 from: <https://pubmed.ncbi.nlm.nih.gov/33448756/>
- 459 32. Pleguezuelos E, Del Carmen A, Llorensi G, Carcole J, Casarramona P, Moreno E, et al.  
460 Severe loss of mechanical efficiency in COVID-19 patients. *J Cachexia Sarcopenia Muscle*  
461 [Internet]. 2021 Aug 1 [cited 2022 Sep 14];12(4):1056–63. Available from:  
462 <https://pubmed.ncbi.nlm.nih.gov/34102017/>
- 463 33. Swenson KE, Swenson ER. Pathophysiology of Acute Respiratory Distress Syndrome and  
464 COVID-19 Lung Injury. *Crit Care Clin*. 2021 Oct 1;37(4):749–76.
- 465 34. Roberts P, Wertheimer J, Park E, Nuño M, Riggs R. Identification of Functional Limitations  
466 and Discharge Destination in Patients With COVID-19. *Arch Phys Med Rehabil*. 2021 Mar  
467 1;102(3):351–8.
- 468 35. Lipworth B, Manoharan A, Anderson W. Unlocking the quiet zone: the small airway asthma  
469 phenotype. *Lancet Respir Med*. 2014 Jun 1;2(6):497–506.
- 470 36. McNulty W, Usmani OS. Techniques of assessing small airways dysfunction. *Eur Clin Respir*  
471 *J* [Internet]. 2014 Jan [cited 2023 Feb 21];1(1):25898. Available from:  
472 </pmc/articles/PMC4629724/>
- 473 37. Fusco A, Padua L, Coraci D, Loreti C, Castelli L, Costantino C, et al. Developing pulmonary  
474 rehabilitation for COVID-19: Are we linked with the present literature? a lexical and  
475 geographical evaluation study based on the graph theory [Internet]. Vol. 10, *Journal of*  
476 *Clinical Medicine*. *J Clin Med*; 2021 [cited 2022 Sep 14]. Available from:  
477 <https://pubmed.ncbi.nlm.nih.gov/34945063/>

- 478 38. Lorent N, Weygaerde Y Vande, Claeys E, Fajardo IGC, De Vos N, De Wever W, et al.  
479 Prospective longitudinal evaluation of hospitalised COVID-19 survivors 3 and 12 months  
480 after discharge. ERJ Open Res [Internet]. 2022 [cited 2022 Sep 14];8(2). Available from:  
481 <https://pubmed.ncbi.nlm.nih.gov/35415186/>
- 482 39. Rayegani SM, Bozorgmehr R, Oshnari LA, Kaghazi AHM. The Effect of Exercise-Based  
483 Pulmonary Rehabilitation on Quality of Life in Recovered COVID-19 Patients; a Quasi-  
484 Experimental Study. Arch Acad Emerg Med [Internet]. 2022 [cited 2022 Sep 14];10(1).  
485 Available from: <https://pubmed.ncbi.nlm.nih.gov/35765605/>
- 486 40. Hayden MC, Limbach M, Schuler M, Merkl S, Schwarzl G, Jakab K, et al. Effectiveness of  
487 a three-week inpatient pulmonary rehabilitation program for patients after covid-19: A  
488 prospective observational study. Int J Environ Res Public Health [Internet]. 2021 Sep 1 [cited  
489 2022 Sep 14];18(17). Available from: <https://pubmed.ncbi.nlm.nih.gov/34501596/>  
490